The Broad Institute of MIT and IBM Watson Health has extended a collaborative deal with IBM Watson Health . The five-year agreement follows the previous 2016 deal signed in three-year and will involve using AI to analyse and examine genomics data to better establish the natural possibility people have for a certain disease. By putting the full force of our clinical and research team together with two of the world’s Together IBM Watson Health and the Massachusetts -based IBM division aim to improve and grow genetic risk scoring by utilising population and hospital-based biobank information, genomic data and electronic health records. Ultimately the initiative intends to make knowledge gained, along with accompanying tools, available to researchers.
The Broad Institute of MIT and IBM Watson Health has extended a collaborative deal with IBM Watson Health . The five-year agreement follows the previous 2016 deal signed in three-year and will involve using AI to analyse and examine genomics data to better establish the natural possibility people have for a certain disease. Together IBM Watson Health and the Massachusetts -based IBM division aim to improve and grow genetic risk scoring by utilising population and hospital-based biobank information, genomic data and electronic health records. Ultimately the initiative intends to make knowledge gained, along with accompanying tools, available to researchers.